Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients

Transplantation

Volumn 63, Issue 10, 1997, Pages 1495-1500

  Korom, Stephan ^a   De Meester, Ingrid ^b   Stadlbauer, Thomas H W ^a   Chandraker, Anil ^a   Schaub, Meike ^a   Sayegh, Mohamed H ^a   Belyaev, Alexander ^b   Haemers, Achiel ^b   Scharpé, Simon ^b   Kupiec Weglinski, Jerzy W ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; BIPHENYL; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; PHOSPHONIC ACID DERIVATIVE; PRODIPINE; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME INHIBITION; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOREGULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIXED LYMPHOCYTE REACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD26; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MALE; PIPERIDINES; PROTEASE INHIBITORS; RATS; RATS, INBRED BN; RATS, INBRED LEW; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 17144446373     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199705270-00021     Document Type: Article

References (35)

1. Fox DA, Hussey RE, Fitzgerald KA, et al. Tal, a novel 105 KD human T cell activation antigen defined by monoclonal antibody. J Immunol 1984; 133: 1250.
2. Dang NH, Hafler D, Schlossman SF, Breitmeyer J. FcR-mediated cross-linking of Tal (Cdw26) induces human T lymphocyte activation. Cell Immunol 1990; 125: 42.
3. Bednarczyk J, Caroll SM, Marin C, McIntyre B. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 1991; 46: 206.
4. + cells through CD26: the ADA binding epitope is not essential for complete signaling. J Leukoc Biol 1995 58: 325.
5. Tanaka T, Camerini D, Seed B, et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992 149: 481.
6. Torimoto Y, Dang N, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 1991; 147: 2514.
7. De Meester I, Vanham G, Kestens L, et al. Binding of adenosine deaminase to the lymphocyte surface via CD26. J Immunol 1994; 24: 566.
8. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993; 261: 466.
9. Yaron A, Naider F. Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem 1993; 28: 31.
10. Vanhoof G, Goosens F, De Meester I, Hendriks D, Scharpé S. Proline motifs in peptides and their biological processing. FASEB J 1995; 9: 736.
11. Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Immunology 1993; 90: 458.
12. Vanhoof G., De Meester I, Van Sande M, Scharpé S, Yaron A. Distribution of proline-specific aminopeptidase in human tissues and body fluids. Eur J Clin Chem Clin Biochem 1992; 30: 333.
13. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. A novel form of dipeptidyl peptidase IV found in human serum. J Biol Chem 1995; 270: 14107.
14. Maes M, Scharpé S, De Meester I, et al. Components of biological variation in prolyl endopeptidase and dipeptidyl peptidase IV activity in plasma of healthy subjects. Clin Chem 1994; 40: 1686.
15. Schön E, Jahn S, Kiessig ST, et al. The role of dipeptidyl peptidase IV in human T lymphocyte activation: inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 1987; 17: 1821.
16. Flentke GR, Munoz E, Huber BT, et al. Inhibition of dipeptidyl aminopeptidase type IV by Xaa boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci USA 1991; 88: 1556.
17. Kubota T, Flentke GR, Bachovchin WW, Stollar BD. Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol 1992; 89: 192.
18. Scharpé S, De Meester I, Vanhoof G, et al. Serum dipeptidyl peptidase IV activity in transplant recipients. Clin Chem 1990; 36: 984.
19. De Meester I, Lambeir AM, Belyaev A, et al. In vivo inhibition of dipeptidyl peptidase IV (DPP IV) by Pro-Pro-diphenyl phosphonate (Prodipine). Biochem Soc Trans 1996; 24: 630S.
20. Lambeir AM, Borloo M, De Meester I, et al. Dipeptidyl-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl-peptidase IV. Biochim Biophys Acta 1996; 1290: 76.
21. Scharpé S, De Meester I, Vanhoof G, et al. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphtylamine. Clin Chem 1988; 34: 2299.
22. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248.
23. Morimoto C, Schlossman SF. CD26 a key costimulatory molecule on CD4 memory T cells. The Immunologist 1994; 2(1): 4.
24. Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 1985; 312: 1405.
25. Muscat C, Bertotto A, Agea O, et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994; 98: 252.
26. Vanham G, Kestens L, De Meester I, et al. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T cells in lymphocytes of HIV-infected subjects. J AIDS 1993; 6: 749.
27. Fujita K, Hirano M, Ochiai J, et al. Serum glycylpropryl p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythematosus. Clin Chim Acta 1978; 88: 15.
28. Kubota T, Iizuka H, Bachovchin WW, Stollar BD. Dipeptidyl peptidase IV (DPP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice treated with disease onset. Clin Exp Immunol 1994; 96: 292.
29. Tanaka T, Duke-Cohan JS, Kameoka J, et al. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 1993; 91: 3082.
30. Sanda MG, Pierson R, Smith C, Rose E. Serum dipeptidyl peptidase IV in cardiac transplant recipients. Transplant Proc 1989; 21: 2525.
31. Küllertz G. Die Bedeutung der Aktivitätsbestimmung des Enzyms Dipeptidyl-Dipeptidase IV (DP IV) im klinischen Laboratorium. Lab Med 1988; 12: 123.
32. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. Serum high molecular weight dipeptidyl peptidase VI (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol 1996; 156: 1714.
33. Schön E, Demuth HU, Eichmann E, et al. Dipeptidyl peptidase IV in human T lymphocytes: impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol 1989; 29: 127.
34. Schmidbauer G, Hancock WH, Wasowska B, Badger AM, Kupiec-Weglinski JW. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation 1994; 57: 933.
35. Yin D, Fathman CG. CD-4 positive suppressor cells block allotransplant rejection. J Immunol 1995; 154: 6339.